INVESTOR ALERT: Kirby McInerney LLP Announces Investigation on Behalf of Myriad Genetics, Inc. (MYGN) Investors

Business Wire

NEW YORK--(BUSINESS WIRE)-- The law firm of Kirby McInerney LLP announced today an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ:MYGN) investors concerning officers’ possible violations of federal securities laws.

Myriad is a molecular diagnostic company. On March 12, 2018, Myriad disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. The subpoena requested that the Company produce documents relating primarily to the Company's billing to government-funded healthcare programs for the Company's hereditary cancer testing.

On this news, Myriad’s share price fell from $33.01 to close at $29.01 on March 13, 2018 (a decline of $4.01).

If you purchased or otherwise acquired Myriad securities, have information or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: http://www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.